P1652: SAFETY OF DOACS IN PATIENTS WITH CHRONIC KIDNEY DISEASE: A SYSTEMATIC REVIEW AND META-ANALYSIS
Bibliographic record
Abstract
Topic: 34. Thrombosis and vascular biology - Biology & Translational Research Background: Direct oral anticoagulants (DOACs) are now the standard of care for management of venous thromboembolism (VTE) and stroke prophylaxis in atrial fibrillation. Patients with chronic kidney disease (CKD) are at increased risk of VTE and atrial fibrillation. As DOACs are partially renally cleared and patients with CrCl<25-30 were excluded from large trials, there remains question of the safety of DOACs in patients with CKD. Aims: To synthesize primary evidence on the safety profile of DOACs in patients with CKD. Methods: We conducted a search of MEDLINE and Embase from database inception to January 2023. We included randomized controlled trials (RCTs) and cohort studies of any DOACs compared to vitamin K antagonists for prevention of thrombosis in patients with CKD. Two reviewers screened and extracted data at title/abstract and full-text levels individually and in duplicate. Baseline characteristics, anticoagulation regimen, and CKD stage were extracted. Primary outcome was ISTH major bleeding stratified by CKD stage. Data were meta-analyzed using random-effects model and presented as odds ratios with corresponding 95% confidence intervals. Results: Of the 2772 articles screened, 33 cohort studies and 7 RCTs comprised of 283690 patients were included. There was a non-significant reduction of major bleeding that favored DOACs for stage 3 CKD (OR=0.78 [0.59, 1.05]), stage 4 CKD (OR=0.82 [0.52, 1.25]), and stage 5 CKD (OR= 0.84 [0.58, 1.21]). Summary/Conclusion: In this preliminary analysis comparing DOACs to VKAs, DOACs were associated with a statistically non-significant reduction in major bleeding across stage 3-5 CKD. Further analyses are in process which will stratify by DOAC agent, duration, dosage, renal replacement therapy, and include secondary efficacy outcomes. Figure 1. DOAC vs Vitamin K Antagonist for the Risk of Major Bleeding Stratified by CKD StageKeywords: Venous thromboembolism, Oral anticoagulant, Chronic renal failure
Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.
How this classification was reachedexpand
Full frame distilled prediction
Teacher imitationNot calibrated prevalence, not ground truth. Human validation pending. Learned from the 10,348 direct Codex labels and 10,348 direct Gemma labels. Candidate is the union of thresholded teacher heads; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels or direct frontier model labels.
Codex and Gemma teacher scores by category
| Category | Codex | Gemma |
|---|---|---|
| Metaresearch | 0.000 | 0.000 |
| Meta-epidemiology (narrow) | 0.000 | 0.000 |
| Meta-epidemiology (broad) | 0.010 | 0.002 |
| Bibliometrics | 0.000 | 0.002 |
| Science and technology studies | 0.000 | 0.000 |
| Scholarly communication | 0.000 | 0.000 |
| Open science | 0.000 | 0.000 |
| Research integrity | 0.000 | 0.000 |
| Insufficient payload (model declined to judge) | 0.001 | 0.000 |
Machine scores (provisional)
The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.
Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.
score_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from itClassification
machine, unvalidatedMachine predicted; a candidate call from one teacher head, not a consensus.
How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".